Abstract
The traditional approaches in heart disease prediction across a vast amount of data encountered a huge amount of class imbalances. Applying the conventional approaches that are available to resolve the class imbalances provides a low recall for the minority class or results in imbalance outcomes. A lightweight GrowNet-based architecture has been proposed that can obtain higher recall for the minority class using the Behavioral Risk Factor Surveillance System (BRFSS) 2022 dataset. A Synthetic Refinement Pipeline using Adaptive-TomekLinks has been employed to resolve the class imbalances. The proposed model has been tested in different versions of BRFSS datasets including BRFSS 2022, BRFSS 2021, and BRFSS 2020. The proposed model has obtained the highest specificity and sensitivity of 0.74 and 0.81 respectively across the BRFSS 2022 dataset. The proposed approach achieved an Area Under the Curve (AUC) of 0.8709. Additionally, applying explainable AI (XAI) to the proposed model has revealed the impacts of transitioning from smoking to e-cigarettes and chewing tobacco on heart disease.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Behavioral Risk Factor Surveillance System https://www.cdc.gov/brfss/index.html
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
